Carbachol 2.75% / Brimonidine Tartrate 0.1% · ophthalmic solution
Aesthetics/Presbyopia
Approved uses
Presbyopia in adults
One drop in each eye once daily
Pairs a cholinergic agonist with an alpha agonist, so miosis comes with a whitening effect
Contraindications
Known hypersensitivity to the active ingredients or to any of the excipients.
2.75% / 0.1% (27.5 mg/mL / 1 mg/mL) ophthalmic solution, 30 single-dose vials of 0.16 mL
The proposed mechanism of action of this fixed-dose combination of carbachol and brimonidine in presbyopia is pupillary constriction and the creation of a pinhole effect that improves near visual acuity and depth of focus.
Warnings & Precautions
- Blurred vision: Miotics may cause accommodative spasm, and patients may experience temporary dim or dark vision with miotics. Advise patients not to drive or operate machinery if vision is not clear, and to exercise caution in night driving and other hazardous activities in poor illumination.
- Retinal detachment: Rare cases of retinal tear and detachment have been reported with miotics, and individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.
- Iritis: Adhesions (synechiae) between the iris and the lens may be exacerbated with miotic use, so YUVEZZI is not recommended to be used when iritis is present.
- Contact lenses: remove them before instillation, and wait 10 minutes after dosing before reinserting them.
- Vascular insufficiency: YUVEZZI may potentiate syndromes associated with vascular insufficiency; use with caution in depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.
- Eye injury or contamination: avoid touching the single-dose vial to the eye, eyelids or any other surface.
Common Side Effects
Most common adverse reactions (incidence >5%) are eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache.
Pregnancy: There are no adequate and well-controlled studies in pregnant women. YUVEZZI was not teratogenic in pregnant rats or rabbits given topical ocular doses up to approximately 3 times the MRHOD throughout organogenesis; rabbits at that dose showed maternal toxicity with no effect on the fetus. Administer during pregnancy only if the potential benefit justifies the potential risk to the pregnant mother and fetus.
Lactation: There is no information regarding the presence of carbachol and brimonidine tartrate in human milk, the effects on the breastfed infants, or the effects on milk production. Systemic levels following topical ocular administration are low.
Presbyopia does not occur in the pediatric population.